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Abstract
It is often of interest to explore how dose affects the toxicity and
efficacy properties of a novel treatment. In oncology, efficacy is often
assessed through response, which is defined by a patient having no
new tumour lesions and their tumour size shrinking by 30%. Usually
response and toxicity are analysed as binary outcomes in early phase
trials. Methods have been proposed to improve the efficiency of analysing
response by utilising the continuous tumour size information instead of
dichotomising it. However these methods do not allow for toxicity or for
different doses. Motivated by a phase II trial testing multiple doses of
a treatment against placebo, we propose a latent variable model that
can estimate the probability of response and no toxicity (or other related
outcomes) for different doses. We assess the confidence interval coverage
and efficiency properties of the method, compared to methods that do
not use the continuous tumour size, in a simulation study and the real
study. The coverage is close to nominal when model assumptions are
met, although can be below nominal when the model is misspecified.
Compared to methods that treat response as binary, the method has
confidence intervals with 30-50% narrower widths. The method adds
considerable efficiency but care must be taken that the model assumptions
are reasonable.
Keywords
Augmented binary method; Composite endpoints; Efficacy/toxicity;
Phase I/II.
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Introduction
Traditionally phase I trials of a new drug are carried out to identify
a safe dose. Once a suitable dose is identified, it is tested for initial
signs of efficacy in a phase II trial. A recent trend is that more trials,
known as phase I/II, consider how the dose of a treatment affects both
efficacy and toxicity at the same time. In oncology, for example, phase
I trials are increasingly using dose expansion cohorts to assess for early
signs of efficacy [1]; in addition, seamless phase I/II trials have been
recommended for improving the efficiency of the drug development
process [2].
For trials which have the objective of exploring the effect of dose
on both toxicity and efficacy, there are two main statistical questions
of interest. The first is the best choice of design to identify a suitable
dose in an efficient and ethical way. Many papers have proposed novel
adaptive designs that allow this, including [3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15]. A recent book[16] provides an overview of Bayesian
methods in this area. The second, related, issue is how to model the
data gathered during such a trial at the end. This is important, as
the purpose of the trial is to choose the most suitable dose to take
forward for a more definitive trial. Many papers that propose adaptive
designs also consider suitable models for efficacy and toxicity data. We
consider the second question in this paper, motivated by the question
of how one could better analyse the probability of early response and
no toxicity in an oncology phase II trial that tested two doses of a novel
treatment against placebo. Although we primarily consider oncology
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in this paper, the methods are applicable to any clinical area where
efficacy is assessed with a responder-based composite outcome.
Toxicity and efficacy in oncology are usually measured with
composite endpoints. In solid tumours, efficacy is evaluated using the
RECIST v1.1 criteria [17] (henceforth referred to as RECIST) which
categorises patients into complete response, partial response, stable
disease and progressive disease according to the change in the sum of
longest diameter of target lesions (henceforth simply called tumour
size) and other criteria for treatment failure such as whether or not
new lesions appear and unacceptable growth in non-target lesions.
A standard early measure of efficacy is the response rate, which is
the proportion of patients who have a partial or complete response.
Toxicity is generally measured using a suitable set of criteria, such
as the Common Toxicity Criteria (CTC) [18], which grades different
types of adverse events between 1 and 5 depending on severity
(with a grade of 3 or above being classed as a severe toxicity).
Often toxicity and efficacy are analysed as binary endpoints with
suitable models used to account for correlation. Some papers have
proposed analysing the variables as ordinal [12, 19, 20, 21]. Others
have considered jointly modelling a binary toxicity outcome and a
continuous efficacy outcome [6, 22, 23] with the continuous outcome
representing a biomarker expression or change in tumour size. In
the case of modelling the joint probabilities of efficacy and toxicity,
with efficacy defined using the commonly used RECIST criteria,
existing methods for jointly modelling a binary toxicity outcome and
a continuous efficacy outcome are not sufficient. This is because the
RECIST efficacy outcome is not purely continuous but is instead a
composite of a continuous outcome (change in tumour size) and binary
(new lesions appearing).
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In previous work [24] we proposed a method for making inferences
on this composite efficacy outcome by fitting a joint model to the
continuous and binary efficacy components. This makes inference on
the clinically relevant response outcome but considerably improves the
efficiency compared to modelling the binary composite outcome alone.
The efficiency gain comes from utilising the continuous nature of
change in tumour size rather than dichotomising it. To our knowledge,
there has been no work on modelling how dose affects the binary
toxicity and a dichotomised binary efficacy outcome, whilst utilising
continuous information to improve efficiency.
In this paper we develop the method of Wason and Seaman[24] so
that it can be used when toxicity is a component of the outcome and
there are multiple doses of the same treatment. A multivariate probit
model with latent variables for toxicity and new lesion events is used
to jointly model the toxicity and the two components of the efficacy
outcome. In this paper we concentrate on estimating the probabilities
of the four possible combinations of efficacy and toxicity (efficacy and
toxicity, efficacy without toxicity, toxicity without efficacy, no efficacy
and no toxicity), primarily focusing on the probability of efficacy
without toxicity. This quantity is likely to be of considerable interest,
as it represents providing patient benefit without unacceptable side-
effects. A dose that maximises this quantity will be desirable to take
forward to further testing. If other quantities involving response as
a binary outcome are of interest, then the method presented here
will also provide benefits for estimating them. Following much of the
previous work in the area, we consider toxicity as a binary outcome.
In the discussion we describe how the method might be extended to
allow for more complex toxicity information.
A previously proposed method for phase I/II trials by Zhong et
al[10] used a trivariate model for toxicity, efficacy and a more quickly
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observed intermediate efficacy marker. Although our method also
assumes a trivariate model, both the aim of the method and the model
used are different.
As the motivation for the methods in this paper we use the
example of the HORIZON II trial [25] (clinicaltrials.gov identifier
NCT00384176). HORIZON II is a phase II trial that tested two doses
of cediranib (20mg once daily, 30mg once daily) against placebo for
the treatment of metastatic colorectal cancer. All patients received
infusional fluorouracil, leucovorin, capecitabine and oxaliplatin. We
were interested in how one could analyse the effect of dose on the
probability of efficacy without toxicity at 6 weeks. This type of
outcome is consistent with early phase I/II trials where short-term
response outcomes are often used.
The rest of the paper is organised as follows. In Section 2 we define
the notation use, and describe the proposed method together with
the comparator methods. In Section 3 we describe the simulation
study setup and results. In Section 4 we present the analysis of
the HORIZON II trial. In Section 5 we summarise the benefits and
limitations of the proposed method and discuss potential future work.
Methods
Notation
We consider a set of N patients. The dose (or some suitable
transformation of it) given to patient i is denoted by di. The ith
patient has baseline tumour size yi0, and a single follow-up tumour
size measurement of yi1. As in Wason and Seaman[24], we work with
the log tumour size ratio, defined as:
zi1 = log
(
yi1
yi0
)
. (1)
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This is used because it has been found to be close to normally
distributed in real data [26]. Other transformations can be used with
minor modification to proposed methods.
In addition to the tumour size data, we also observe whether a
patient had an efficacy failure for reasons other than an increase in
tumour size (henceforth referred to as non-shrinkage failure). This
could be due to new lesions, or an unacceptable increase in the
size of non-target lesions. This is summarised by an indicator Fi,
which equals 1 if a non-shrinkage failure occurred and 0 otherwise. A
separate indicator Ti is equal to 1 if a dose-limiting toxicity occurred
and 0 otherwise.
Augmented binary method using a latent variable model
In Wason and Seaman, separate models were fitted for the tumour
sizes and for the non-shrinkage failure indicators. The tumour size
data were modelled using a multivariate normal model and the non-
shrinkage failure data by a series of logistic regression models. Each
logistic regression modelled the probability of having a non-shrinkage
failure at a certain visit conditional on not having one up to that
time and on the tumour size at the beginning of that time period.
This allowed correlation between the tumour sizes and non-shrinkage
failure indicators to be accounted for, although in a restricted way.
In this paper we propose using an alternative model that allows
for correlation between the three components of the efficacy without
toxicity outcome. Although one could combine toxicity and non-
shrinkage failure and apply the method from Wason and Seaman,
this would not model the possibly different relationships between dose
and the probabilities of new lesions and toxicity. For example, it is
plausible that increasing dose may increase the probability of toxicity
but decrease the probability of new lesions. The model we use is
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related to the multivariate probit model discussed in, for example,
Chib and Greenberg [27].
The model uses log tumour ratio of patient i, Zi1 and two latent
normally distributed random variables Zi2 and Zi3. These are related
to Fi and Ti through Fi = I{Zi2 > 0} and Ti = I{Zi3 > 0} , where
I{.} represents the indicator function. We focus on a model that
allows each component to depend linearly on the dose, but later
on more complex relationships are considered. We also allow each
component to depend on baseline tumour size. It is plausible that
change in tumour size, probability of new lesions and probability of
toxicity are each associated with the tumour size at baseline. Thus
adjusting for baseline tumour size will improve the precision of other
parameter estimates. Other covariates can be adjusted for in a similar
manner. The model with linear dependence on dose is:
Zi1 = µ1 + α1di + β1yi0 + εi1
Zi2 = µ2 + α2di + β2yi0 + εi2
Zi3 = µ3 + α3di + β3yi0 + εi3, (2)
where the residual error terms have the following distribution:
(εi1, εi2, εi3) ∼ N(0,Σ)
Σ =
 σ
2
1 ρ12σ1 ρ13σ1
ρ12σ1 1 ρ23
ρ13σ1 ρ23 1
 . (3)
As is common in multivariate probit models, the error variances of
the latent variables are set to 1 for identifiability reasons.
Let θ = (µ1, α1, β1, µ2, α2, β2, µ3, α3, β3, σ
2
1, ρ12, ρ13, ρ23). The likeli-
hood contribution for individual i, l(θ;Zi1, Zi2, Zi3, di, yi0) can be
written as:
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l(θ;Zi1, Zi2, Zi3, di, yi0) = f(Zi1|di, yi0; θ)f(Zi2, Zi3|Zi1, di, yi0; θ), (4)
the product of the marginal pdf for Zi1 (conditional on yi0 and di)
and the joint pdf for Zi2 and Zi3, conditional on Zi1, yi0 and di.
The marginal pdf of Zi1 is normal with mean µ1 + α1di + β1yi0 and
variance σ21. The conditional distribution of (Zi2, Zi3) given Zi1 is
bivariate normal with mean µ˜ and covariance matrix Σ˜, where:
µ˜ =
(
µ2 + α2di + β2yi0
µ3 + α3di + β3yi0
)
+
1
σ21
(
ρ12σ1
ρ13σ1
)
(Zi1 − µ1 − α1di − βiyi0)
Σ˜ =
(
1 ρ23
ρ23 1
)
− 1
σ21
(
ρ212σ
2
1 ρ12ρ13σ
2
1
ρ12ρ13σ
2
1 ρ
2
13σ
2
1
)
,
which are derived from standard properties of the multivariate normal
distribution (see, for example, [28]). For notational convenience we
drop the conditioning on di and yi0.
Since Zi2 and Zi3 are not observed directly, the contribution of
patient i to the likelihood is:
f(Zi1; θ)
∫
A(Fi)
∫
A(Ti)
g2(x, µ˜, Σ˜)dx, (5)
where A(u) = (0,∞) if u = 1 and (−∞, 0) if u = 0. Here, gK(x,m, S)
denotes the pdf of a K-dimension normal distribution with mean m
and covariance matrix S, evaluated at x.
The likelihood function is maximised to find the maximum
likelihood estimator (MLE) of θ, θˆ. To do this in an efficient manner,
the integrals in (5) are evaluated using the method of Genz and
Bretz[29], which is a highly efficient Monte-Carlo integration method
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that can be used for integrating over the multivariate normal or t-
distribution. The overall optimisation is done using optim in R [30]
with the “BFGS” option used. The covariance matrix of the MLE,
is estimated as Ĉov(θˆ), the inverse of the Hessian matrix. To ease
estimation, we introduce parameters δ = (δ1, δ12, δ13, δ23) such that:
σ21 = exp(δ1)
ρjk = 2
exp(δjk)
1 + exp(δjk)
− 1 (j, k) ∈ {(1, 2), (1, 3), (2, 3)}, (6)
These reparameterisations induce the required range for the variance
and correlation parameters while allowing estimation of parameters
that can take any real value.
Once θˆ and Ĉov(θˆ) are calculated, we can find the predicted
probability of various combinations of toxicity and efficacy given a
certain dose. Table 1 shows the various events that may be of interest
in a dose-finding trial, and how they can be expressed as integrals
over the joint distribution of Zi = (Zi1, Zi2, Zi3).
For example, the probability of efficacy without toxicity in
individual i with baseline tumour size yi0 and dose di, pET¯ , is:
pET¯ (di, yi0) =
∫ 0
−∞
∫ 0
−∞
∫ log(0.7)
−∞
g3
(
(zi1, zi2, zi3), µ¯(di, yi0), Σ¯
)
dzi1dzi2dzi3,
where µ¯(di, yi0) =
 µ1 + α1di + β1yi0µ2 + α2di + β2yi0
µ3 + α3di + β3yi0
, and Σ¯ =
 σ
2
1 ρ12σ1 ρ13σ1
ρ12σ1 1 ρ23
ρ13σ1 ρ23 1
 . The upper limit of log(0.7) comes
from response being defined by a greater than 30% shrinkage from
baseline, equivalent to the log tumour size ratio being less than
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log(0.7). The estimated probability of pET¯ (d, yi0), pˆET¯ (d, yi0), has
the same form but with all true parameter values replaced by their
MLEs.
We are typically interested in the average probability of efficacy
without toxicity across all individuals with baseline tumour sizes
y0 = (y10, . . . , yN0) were they given dose d, defined as piET¯ (d) =∑N
i=1 pET¯ (d, yi0)
N
, with its estimate pˆiET¯ (d) =
∑N
i=1 pˆET¯ (d, yi0)
N
.
To estimate the variance of pˆiET¯ (d), we can use the delta method:
Var(pˆiET¯ ) ≈ (5pˆiET¯ )T Ĉov(θˆ)(5pˆiET¯ ), (7)
where 5pˆiET¯ is the vector of partial derivatives of pˆiET¯ with respect
to each entry of θ. These are evaluated numerically. The estimated
variance in equation (7) can be used to form a 95% confidence interval
(CI) for piET¯ :(
pˆiET¯ (d)− Φ−1
(
1− α
2
)√
Var(pˆiET¯ (d)), pˆiET¯ (d) + Φ
−1
(
1− α
2
)√
Var(pˆiET¯ (d))
)
. (8)
As shown in Wason and Seaman[24], the coverage of the CI may be
improved if one works on the log-odds scale instead of the probability
scale, especially if the average probability is near to 0 or 1.
After the model has been fitted, this process can be repeated for
a range of doses to get a plot of the relationship between d and the
quantity of interest, e.g. pˆiET¯ (d). Both the estimated quantity and
confidence bands are yielded from this procedure.
We henceforth refer to this approach as the augmented binary
method, although in fact it is an extension of the original augmented
binary method to allow for toxicity and dose dependence.
Binary methods
We compare the proposed method to two methods that use the
dichotomised efficacy outcome only. The first, referred to as binary 1,
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is, for each dose given to patients, to estimate the quantity of interest
as the observed proportion together with 95% CI using a Wilson
interval (binconf in the Hmisc package of R). This method does not
attempt to model the relationship between dose and efficacy/toxicity
and in particular cannot estimate a probability of efficacy without
toxicity for a dose not given.
The second method, binary 2, fits a logistic regression to the binary
indicator of the outcome of interest with parameters for baseline
tumour size, dose and dose squared. We include linear and quadratic
terms for dose to allow flexibility in the dependence of dose on
probability of efficaccy without toxicity, however alternative models,
such as splines, could be used if the sample size allows. The model is:
log
(
p
1− p
)
= µ+ α1di + α2d
2
i + β1yi0, (9)
where p is the probability of the outcome of interest.
From the model in equation (9), the parameter estimates are used to
get predicted probability of the quantity of interest for each individual
in the study had they been given dose d. The mean of this quantity
(e.g. piET¯ (d) when the outcome of interest is efficacy without toxicity),
and a CI estimated from the delta method, can be found for different
values of d to form a dose-response curve with 95% confidence bands.
Simulation studies
To understand the operating characteristics of the three methods,
we performed a set of simulation studies. In all cases we assume five
doses (d ∈ (0, 1, 2, 3, 4)) are available with an equal number of patients
allocated to each. Although this is a larger number than the three
doses tested in the case study (described later), we felt this would
better represent potential wider applications to early-phase trials.
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Simulation study methods
In the first simulation study, we explored the properties of the
augmented binary method when the assumptions made by the model
are broadly true. In all cases the baseline tumour size, yi0, is simulated
as a Uniform(1,10) random variable. Given dose, di, and yi0, the log
tumour size ratio Zi1 is assumed to follow a normal distribution with
variance 1 and mean equal to an intercept and a linear effect of dose.
The log odds of toxicity and new lesions also (separately) depend
linearly on dose. Mathematically:
Zi1 = µ1 + α1di + εi1
P(Fi = 1|di, Zi1) = expit(µ2 + α2di)
P(Ti = 1|di) = expit(µ3 + α3di), (10)
where εi1 ∼ N(0, σ2) is independent of di and expit(x) = exp(x)1+exp(x) . In
this case, conditional on dose, the three variables are independent.
The values for µ1, α1, µ2, α2, µ3, α3 are chosen to form four different
scenarios. Table 2 shows the parameter values used in the four
scenarios. We note that the data-generating model (10) uses the
logistic link whereas the analysis model uses the probit link. This
is the case so that sensitivity of results to the simulation assumptions
being different to the augmented model assumptions could be
assessed.
Scenario 1 represents no effect of dose on any of the outcomes.
Scenario 2 represents a cytotoxic drug where increasing dose leads
to better tumour shrinkage and a reduced chance of new lesions but
higher toxicity. Scenario 3 represents a cytostatic drug that reduces
the probability of new lesions but does not affect tumour size or
toxicity. Scenario 4 represents an ineffective and toxic drug where
increased dose leads to higher toxicity but no change in efficacy.
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In all cases we assumed that 15 patients had been treated with each
of five doses d = (0, 1, 2, 3, 4), thus 75 patients in total. For scenario
1 we also considered having 6 patients per dose and 25 patients per
dose, to determine if there was a noticeable effect of the sample size
on the properties of the method.
We estimated the statistical properties of the three methods using
the true dose-response relationship yielded from the underlying
model. In particular we estimated the coverage, the width of the
confidence interval, the bias and mean squared error for each method;
we also estimated the width of the confidence band and mean absolute
error (i.e. the expected absolute difference between predicted and true
values) across the range of doses for the binary 2 and augmented
binary method. These latter two quantities were found for a range of
doses between 0 and 4, with the trapezium rule used to approximate
the integral of the quantity between d=0 and 4.
The second simulation study explored the situation where the
probability of toxicity was associated with the log tumour size ratio
(inducing a correlation). This was done by simulating the data using
the following equations:
Zi1 = µ1 + α1di + εi1
P(Fi = 1|di, Zi1) = expit(µ2 + α2di)
P(Ti = 1|di, Zi1) = expit(µ3 + α3di + β1Zi1 + β2Z2i1). (11)
By changing the value of (β1, β2), the extent of the correlation between
Zi1 and Ti can be varied. We note that the form of this correlation
is not necessarily consistent with the form allowed for in the latent
normal model assumed in the augmented binary analysis method.
Thus, this setup should test whether the results from this method are
sensitive to misspecification of the correlation form.
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The third simulation study examined the properties of the
augmented binary method whendata were simulated using a form for
the probability of toxicity and mean tumour shrinkage that deviated
strongly from the assumed latent variable model. One simulation
scenario used the Emax model (see e.g. Macdougall[31]) for the
toxicity probability; a second used the Emax model for the mean
log-tumour size ratio. The respective models used to simulate data
were:
P(Ti = 1|di, yi0, Zi1) = E0 + (d
λ
iEMax)
(dλi + ED50)
,
E(Zi|di, yi0) = E0 + (d
λ
iEMax)
(dλi + ED50)
(12)
where E0 represents the probability of toxicity or mean log tumour
ratio when di = 0, Emax is the maximum effect attributable to the
drug, ED50 is the dose that gives half the maximum effect, and λ
determines the slope of the curve. In each case, other components
were simulated as in Scenario 1. For the toxicity simulation study, the
value of (E0, EMax,ED50, λ) was set to (0.1, 0.7, 2, 4). For the mean
tumour shrinkage simulation study (E0, EMax,ED50, λ) was set to
(0, log(0.5), 2, 4). We investigated fitting the model given in equation
(2) and the same model but with an additional parameter in the
relevant part of model to allow (respectively) the mean of Zi1 or Zi3 to
depend on the squared-dose. In all simulation studies, 5000 replicates
were used.
Simulation study results
We first present the results of the first simulation study investigating
four different scenarios (described in table 2). In figure 1, we
show the true relationship between dose and probability of efficacy
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without toxicity. Supplementary figure 1 shows the probability of the
individual components (toxicity, tumour shrinkage and new lesions).
In supplementary table 1, the coverage of the two binary methods
and the augmented binary method is provided at the five doses
considered. Each of the methods appears to have around 95% coverage
in most cases. In some situations the coverage appears to be higher or
lower than the nominal level, even allowing for Monte-Carlo standard
error (with 5000 replicates, this is 0.003). There are no cases where the
coverage is worryingly low (the minimum coverage for the augmented
binary method is 0.938).
In case the properties of the method were sensitive to the value of
σ assumed in the simulations, we considered increased values of σ.
Supplementary table 2 shows that this made no difference to the
coverage. We also did a simulation scenario where the number of
patients allocated to dose 2 was three times the number allocated
to other doses - the coverage was unaffected by this also.
Table 3 provides the precision, in terms of the confidence interval
widths, for the three methods in the four scenarios. We present the
average confidence interval width for dose d = 1 and the overall area
within the upper and lower confidence bands between doses 0 and 4
(as found by first calculating CIs for a grid of 100 dose values between
d = 0 and d = 4 and using the trapezium rule to approximate the
area between the confidence bands in the region [0, 4]). The binary 1
method does not give confidence bands, so only the average CI width
for dose 1 is presented for it. The results show that binary 2 improves
the precision at dose 1 compared to binary 1. This indicates that
using a suitable model to borrow strength between data on different
doses improves the precision at each dose. The results show that
making use of the continuous tumour information further improves
the efficiency: both the confidence interval width at dose 1 and the
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area of the confidence band are considerably narrower using the
augmented binary method compared to the binary 2 method.
The bias, mean squared error and expected absolute error are
provided in supplementary tables 3-5. The bias of all methods is
small for all doses. The augmented binary method provides a clear
advantage in the mean squared error and mean absolute error in all
scenarios.
We repeated scenario 1 with 6 patients per arm and 25 patients
per arm to check how the relative performance of the methods may
vary as the sample size changes. These results are presented in
table 3 and supplementary table 1. The augmented binary methods
coverage appears largely unaffected. The binary 2 method appears
to become more conservative for smaller sample sizes. The relative
performance of the methods appears similar for the different sample
sizes considered. We note that the width of the CI found from the Aug
Bin method at d = 1 for n = 15 per dose is slightly narrower than the
width of the Binary 2 method at d = 1 for n = 25.
To investigate the effect of correlation between the different
components of the outcome, we investigated varying β1 in equation
(11), whilst keeping β2 = 0. Supplementary figure 2 shows that the
coverage of the binary 2 and augmented binary methods remain
similar as β1 changes, perhaps decreasing slightly. The binary 1
method has coverage that changes sharply without a clear trend.
This is likely due to the discrete nature of the binomial distribution,
which may affect binary 1 (which does not borrow information over
doses) more severely than it affects the other two methods. We also
investigated the coverage of confidence intervals from the method if
the latent variable model that assumed independence between the
components This was done by fitting the latent variable model with
correlation parameters constrained to be 0. For positive values of β1,
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this led to substantial bias and lower than nominal coverage when
estimating the probability of efficacy without toxicity. For β1 = 1, the
coverage at particular doses was as low as 80%. This indicates that
modelling the correlation is important.
Sensitivity to assumptions
The previous simulation scenarios have been approximately consistent
with the augmented binary model’s assumptions. We conducted
further simulation studies to assess how the method might perform
in scenarios where the model assumptions are further from holding.
We first examined the properties of the augmented binary method
when a non-linear relationship between the dose and log-odds of
toxicity was present. This was done by simulating toxicity data using
the Emax model in equation (12), with all other parameters set as in
scenario 1. In this case the dose has the effect of increasing toxicity
but not efficacy. The augmented binary method using the models in
(2) was fitted. In addition, the method was applied using a modified
model that also included a parameter for the effect of the squared
dose (d2i ) on the toxicity latent variable Zi3. We repeated this but
with an emax model used to simulate the mean log tumour size ratio.
The coverage results for both models in both scenarios are provided
in supplementary table 6. We see that the coverage of the augmented
binary method is highly dependent on being able to model the true
relationship between dose and the respective component reasonably
well. The model described by (2) leads to very poor coverage for some
doses, especially d = 2, which is where the ED50 is. The modified
model that includes a quadratic term does much better, with the
worst coverage being 92.6% at d = 2 for the toxicity scenario.
As a second sensitivity analysis we examined what happened
if a non-zero value of β2 in (11) was used. This represents a
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quadratic effect of the log tumour ratio on the probability of toxicity.
Supplementary figure 3 shows that the coverage appears to be slightly
lower than nominal when β2 is negative. For positive values of β2,
coverage is correct or slightly higher than nominal.
Case study
The HORIZON II trial initially randomised patients 1 : 1 : 1 between
arms. However at an interim analysis the 30 mg dose was closed
to further recruitment and subsequently recruited patients were
randomised 2 : 1 between 20mg and placebo. In total, the numbers
of patients randomised to placebo, 20mg and 30mg were 346, 484 and
209 respectively.
We applied the two binary methods, the augmented binary model
described in equation (2) (referred to as the AugBin linear dose
model) and a slightly more complicated augmented binary model
that added a quadratic dose term for each of the three components
(referred to as the AugBin quadratic dose model):
Zi1 = µ1 + α1di + β1d
2
i + γ1yi0 + εi1
Zi2 = µ2 + α2di + β2d
2
i + γ2yi0 + εi2
Zi3 = µ3 + α3di + β3d
2
i + γ3yi0 + εi3, (13)
The dose scale was standardised so that the value of d used in the
models was 0 for placebo, 1 for 20mg and 2 for 30mg.
We first explored the best transformation to apply to the tumour
size change by finding the best Box-Cox transformation. This
indicated that the tumour ratio (Yi1/Yi0) was closer to normally
distributed than the log tumour ratio Zi1, hence we used the former as
the outcome of the continuous part of the augmented binary models
in (2). The probability of efficacy without toxicity was estimated
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for a grid of standardised doses in the region [0, 2] for the binary
2 method and the two augmented binary methods. The estimated
curves, together with confidence bands, are plotted in figure 2. Table
4 reports the estimated probability of efficacy without toxicity for
each of the three doses together with the confidence band area for the
binary 2 and augmented binary methods.
Both augmented binary methods give substantial reductions in
the confidence interval widths and the area between the upper and
lower confidence bands compared to the binary methods (table 4).
Although it is difficult to determine whether changes to the dose-
response relationship are due to chance, it appears that including a
quadratic term changes the conclusion as to which is the superior dose
including it indicates that 20mg is the dose that best balances safety
and efficacy. When measured by AIC the quadratic model fits slightly
better (difference in AIC of around 1). These results indicate that if
the sample size permits, investigating a range of possible models may
be beneficial.
Discussion
In this paper we have considered trials conducted to explore the
efficacy and toxicity of different doses of a novel treatment. Many
treatments fail later in the drug-development process due to lack of
efficacy or unacceptable toxicity [32, 33], so it is important to ensure
the right dose is chosen to balance these two factors. Methods that
can improve the chance of picking the most suitable dose are therefore
very important.
We have adapted a method [24] that was originally proposed to
improve the efficiency of analyses when the efficacy endpoint is
composite with one continuous component and one binary component.
This is the case for phase II oncology trials where a patient
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is a responder if their target tumour lesions shrink by at least
30% and they do not have any new lesions or other reasons for
treatment failure (such as non-target lesions increasing unacceptably
in size). That method involved fitting a suitable joint model to
the different components and then drawing inferences about the
composite endpoint. This had the property of better utilising the
continuous component, for example by weighting observed responses
less if the patients tumour shrinkage was close to the 30% threshold
than if their shrinkage was much greater than the threshold.
Here, we have adapted that method to allow for a relationship
between dose and the probabilities of toxicity and efficacy. This was
done through a multivariate probit model, where the two binary
components (toxicity and new lesions) are included using latent
variables. This model allows better modelling of correlation between
the two efficacy and one toxicity components than previous methods
allowed. This is particularly important in phase I/II trials, because
for many types of cancer treatment there is likely to be a correlation
between efficacy and toxicity. Although not considered, the method
allows additional covariates to be adjusted for also.
Our simulation study demonstrated that this method can result
in a substantial gain in efficiency compared to methods that do
not exploit the continuous nature of the tumour size, and in the
HORIZON II study the width of the confidence interval for the
probability of efficacy without toxicity was considerably narrower.
The simulation study also showed that the coverage of the confidence
interval is generally close to nominal if model assumptions are
correct. We also assessed the sensitivity of coverage to some of the
model assumptions. It was clear from these investigations that it is
important that the models used for each of the components allow the
modelled relationship to be close to the true one. For example, when
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a non-linear relationship between dose and probability of toxicity
was present, the model performed much better when both linear
and quadratic effects of dose on toxicity were allowed compared to
when just a linear effect was allowed for. The coverage of the model
appeared to remain good when more complicated correlations between
the components of the outcome were simulated.
Several important considerations emerged from the case study. First
it is important to have a good understanding, prior to starting the
trial, of the likely impact of dose on the various components so that
a suitable model can be pre-specified. Different conclusions resulted
from the augmented binary model with just a linear dose term
compared to one with linear and quadratic terms. Generally models
that allow for more flexiblility in the shape of the dose-response
relationship should be preferred if the sample size is sufficiently high.
Second, it is important to transform the tumour shrinkage outcome
appropriately so that the residuals of the model are as close to
normally distributed as possible. The results from the augmented
binary method were quite different when the log tumour ratio was
used as opposed to the Box-Cox transform which resulted in residuals
being closest to normality. Third, there were a small number of
complete responses observed (100% tumour shrinkage) which means
that the assumption of normally distributed outcomes is not met.
Work to apply a more suitable distribution such as the censored
normal distribution [34] might be of use if there is a high proportion
of complete responses. Work is underway to apply the method to a
few different case studies and propose guidelines on a workflow for
applying the method in a trial.
Our results have also concentrated on inferring the dose curve
rather than testing the difference in probability of response without
toxicity of doses against that of control. In phase IIb trials it is often
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of interest to formally test doses against a placebo or control in
terms of efficacy. This would be possible to do using our proposed
method by assuming that placebo/control can be considered as a
dose of 0. Approaches such as MCP-mod [35] have been proposed
to simultaneously allow for uncertainty in the underlying dose-
response curve whilst testing doses against control. This would be
very complementary to the methodology proposed here; investigating
how the two might be combined would be both interesting and help
address issues mentioned in the previous paragraph.
In this paper we have focused on estimating the probability of
efficacy and no toxicity. Other quantities can be estimated using
the method, including the probability of efficacy given a toxicity
constraint and a weighted score of probability and toxicity. In fact,
one benefit of the method is that several of these quantities can be
estimated simultaneously and their joint distribution be found. This
would allow for more efficient control of the type I error rate if multiple
testing correction is required.
We have focused on oncology trials in this paper, motivated by
the HORIZON II dataset. However, the method may be applicable in
several other areas. Trial endpoints that are a composite of continuous
and binary components are used in several other areas. One example is
rheumatoid arthritis [36], where several disease scoring criteria have
this property. It is important to bear in mind that sample sizes in
different disease areas may vary and that the HORIZON II trial
was much larger than would be expected for a typical trial assessing
efficacy and safety of different doses. Previous work by McMenamin
et al [37] has examined the statistical properties of the augmented
binary method for small sample size situations and has proposed
corrections to improve the properties. It would be of interest to extend
this work to the latent variable model used in this paper. On the
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other hand, for trials with large sample sizes it would be of interest to
explore how more flexible modelling approaches such as splines could
be applicable.
There are several extensions to this work which would be of interest.
The first is to apply the method in adaptive phase I/II trials to
help select the next dose. The main issue here would be applying
the method to small samples; this would be especially true for early
interim analyses. It would be possible to use an alternative approach
early on in the trial and switch to using the augmented method
when there are sufficient data available. In this case it would be of
interest to compare the resulting method to current adaptive methods
[3, 4, 5, 6, 7, 8, 9, 11, 12]. Since these methods either analyse response
as binary or categorical (which means they are likely to have less
power), or analyse it as a continuous variable only (which means
they are likely to have less clinical interpretability for RECIST-based
response), the new method is potentially very useful.
A second extension would be to consider more than one follow-up
time. By including more components in the latent variable model,
it would be possible to allow for the efficacy or toxicity endpoint
to be observed at several timepoints. Although possible, having more
timepoints would increase the number of parameters, particularly ones
representing the covariance. It would also be more computationally
complex to maximise the likelihood and perform the multivariate
integration to infer the probability of efficacy without toxicity. Thus,
careful consideration of the correlation structure might be necessary
to avoid having too many parameters or an infeasible computational
burden. Despite these difficulties, it would be worthwhile to pursue
this in order to allow use of the methodology for a wider variety of
phase I/II trials. Some related work on reducing the computational
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burden in the context of multiple efficacy timepoints is presented in
Lin and Wason [38].
A third extension would be to develop the method to use more
detailed information on toxicity. We assumed toxicity was represented
by a binary component, but in fact it is potentially more complex
than this. We could extend the latent variable model to allow for an
ordinal toxicity variable (bringing in grading of observed toxicities).
Going further, a model could be developed that uses the richness
of toxicity data gathered in practice to the fullest extent possible.
Toxicity criteria such as the Common Toxicity Criteria [18] contain
many different components, some of which are based on continuous
values. The challenge would be to fit a suitable model to such a high
number of components, although the resulting efficiency gains may
be even higher than those seen in this work.
In conclusion, we have proposed a method that can substantially
increase the efficiency of trials that assess different doses of a
treatment on both a toxicity and composite efficacy endpoint.
Software
An R package, AugBinDoseFinding is available from
https://sites.google.com/site/jmswason/supplementary-material.
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Figure 1. Actual relationship between dose and probability of efficacy without toxicity in
simulation scenarios.
(a) Scenario 1 (b) Scenario 2
(c) Scenario 3 (d) Scenario 4
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Figure 2. Plot of relationship between standardised dose and probability of efficacy
without toxicity for the binary method and two augmented binary methods. Solid lines
indicate the estimated curve and dotted lines represent the 95% confidence bands
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Table 1. Summary of possible events of interest to model in dose-finding trial
Outcome for
patient
Required events for
this outcome
Modelled probability of event in terms of latent
variable model
Efficacy Fi = 0 and
zi1 < log(0.7)
∫ 0
−∞
∫ log(0.7)
−∞ fZi1,Zi2(z1, z2)dz1dz2
Toxicity Ti = 1
∫∞
0
fZi3(z3)dz3
Efficacy
without
toxicity
Fi = 0, zi1 < log(0.7)
and Ti = 0
∫ 0
−∞
∫ 0
−∞
∫ log(0.7)
−∞ f(Zi1,Zi2,Zi3)(z1, z2, z3)dz1dz2dz3
Efficacy with
toxicity
Fi = 0, zi1 < log(0.7)
and Ti = 1
∫∞
0
∫ 0
−∞
∫ log(0.7)
−∞ f(Zi1,Zi2,Zi3)(z1, z2, z3)dz1dz2dz3
Toxicity
without
efficacy
Ti = 1 and at least
one of Fi = 1 or zi1 >
log(0.7)
∫∞
0
fZi3(z3)dz3−∫∞
0
∫ 0
−∞
∫ log(0.7)
−∞ f(Zi1,Zi2,Zi3)(z1, z2, z3)dz1dz2dz3
No efficacy
and no
toxicity
Ti = 0 and at least
one of Fi = 1 or zi1 >
log(0.7).
∫ 0
−∞ fZi3(z3)dz3−∫ 0
−∞
∫ 0
−∞
∫ log(0.7)
−∞ f(Zi1,Zi2,Zi3)(z1, z2, z3)dz1dz2dz3
Table 2. Description of the four scenarios used in simulation study 1.
Scenario µ1 α1 µ2 α2 µ3 α3
1 - no effect of dose on toxicity or
efficacy
0 0 -1 0 -1 0
2 - cytotoxic drug, shrinks tumour
and increases toxicity
0 -0.4 -1 -0.25 -1.5 0.5
3 - cytostatic drug, reduces proba-
bility of new lesions but does not
increase toxicity
0 0 -1 -0.5 -1.5 0
4 - ineffective and toxic drug -0.3 0 -1 0 -1.5 1
Table 3. Efficiency results in terms of confidence interval width at dose 1 and area
between the upper and lower confidence interval curves across all doses.
Mean CI width for dose d = 1 Confidence band area
Binary 1 Binary 2 Aug Bin Binary 2 Aug Bin
Scenario 1 0.364 0.246 0.167 1.088 0.689
Scenario 2 0.406 0.279 0.204 1.245 0.898
Scenario 3 0.388 0.260 0.185 1.177 0.776
Scenario 4 0.376 0.315 0.189 1.193 0.628
Scenario 1 n = 6 per dose 0.524 0.469 0.263 2.045 1.085
Scenario 1 n = 25 per dose 0.269 0.173 0.119 0.765 0.490
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Table 4. Estimated probability of efficacy without toxicity, confidence interval, and area of
confidence bands for the binary and augmented binary methods when applied to the
HORIZON II dataset.
Method Placebo 20mg 30mg Area of confi-
dence band
Binary 1 0.257 (0.213,0.306) 0.298 (0.259,0.341) 0.276 (0.218,0.343) NA
Binary 2 0.251 (0.207,0.301) 0.289 (0.250,0.333) 0.261 (0.204,0.328) 0.167
Aug Bin linear 0.273 (0.241,0.308) 0.301 (0.278,0.325) 0.325 (0.283,0.369) 0.116
Aug Bin quadratic 0.254 (0.221,0.292) 0.328 (0.296,0.362) 0.291 (0.244,0.342) 0.132
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